Industry & Policy News

[Intellia Therapeutics, Inc. (GlobeNewswire)] Intellia Therapeutics, Inc. announced that the US FDA has cleared the company’s IND application for NTLA-2001 for the treatment of ATTR amyloidosis with cardiomyopathy.

[Metabolon Inc.] Metabolon, Inc., announced the launch of its new Liver Fibrosis and Kidney Function Discovery Panels.

[Fierce Biotech] If Illumina does not complete its task in the next 12 to 15 months, the commission noted it could “impose periodic penalty payments” of up to 5% of the companies’ daily income.

[Rise Therapeutics] Designed specifically to induce regulatory T cells and reset immune balance in patients suffering from autoimmunity, R-2487 works by educating dendritic cells to redirect immune responses away from inflammatory effects.

[Manchester Cancer Research Centre] The charity Breast Cancer Now has awarded £249,992 to Dr Sankari Nagarajan and her team at The University of Manchester to help discover why some TNBCs spread to other parts of the body and whether existing drugs can be repurposed to stop this.

[Bolt Biotherapeutics] Bolt Biotherapeutics announced that the first patient has been dosed with BDC-3042 in the single-agent dose-escalation portion of this first-in-human Phase I/II clinical study. They evaluate BDC-3042 in patients with metastatic or unresectable cancers including triple-negative breast cancer, colorectal cancer, non-small cell lung cancer.